Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Viking Therapeutics (VKTX) over the last 11 years, with Q4 2025 value amounting to $116.1 million.

  • Viking Therapeutics' Change in Acquisitions & Divestments fell 1911.54% to $116.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $759.4 million, marking a year-over-year increase of 3561.11%. This contributed to the annual value of $759.4 million for FY2025, which is 3561.11% up from last year.
  • Viking Therapeutics' Change in Acquisitions & Divestments amounted to $116.1 million in Q4 2025, which was down 1911.54% from $181.5 million recorded in Q3 2025.
  • Viking Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $295.9 million during Q1 2025, with a 5-year trough of $32.3 million in Q1 2022.
  • Over the past 5 years, Viking Therapeutics' median Change in Acquisitions & Divestments value was $65.0 million (recorded in 2021), while the average stood at $100.0 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first crashed by 6185.28% in 2021, then soared by 16304.64% in 2024.
  • Over the past 5 years, Viking Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $63.0 million in 2021, then fell by 17.65% to $51.9 million in 2022, then surged by 156.94% to $133.3 million in 2023, then rose by 7.71% to $143.5 million in 2024, then fell by 19.12% to $116.1 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $116.1 million for Q4 2025, versus $181.5 million for Q3 2025 and $166.0 million for Q2 2025.